vs
Side-by-side financial comparison of AdvanSix Inc. (ASIX) and Varex Imaging Corp (VREX). Click either name above to swap in a different company.
AdvanSix Inc. is the larger business by last-quarter revenue ($359.9M vs $209.6M, roughly 1.7× Varex Imaging Corp). Varex Imaging Corp runs the higher net margin — 1.1% vs -0.8%, a 1.9% gap on every dollar of revenue. On growth, AdvanSix Inc. posted the faster year-over-year revenue change (9.4% vs 4.9%). AdvanSix Inc. produced more free cash flow last quarter ($36.1M vs $-26.8M). Over the past eight quarters, AdvanSix Inc.'s revenue compounded faster (3.4% CAGR vs 0.8%).
AdvanSix Inc. is an American chemical company that produces nylon 6 and related chemicals such as caprolactam and ammonium sulfate fertilizers. It operated as Honeywell's Resins and Chemicals division until 2016, when it was spun off as a separate company. The unit accounted for 3 percent of Honeywell's sales at the time. For 2019, revenue is estimated at $1.4 billion. The company traces its lineage to the H. W. Jayne Company, established 1884 in Frankford, Pennsylvania.
Varex Imaging Corp is a global supplier of advanced imaging components and solutions, including X-ray tubes, digital flat panel detectors, and image processing software. Its products serve medical imaging, radiation oncology, and industrial non-destructive testing segments, with customers across key global markets.
ASIX vs VREX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $359.9M | $209.6M |
| Net Profit | $-2.8M | $2.3M |
| Gross Margin | 7.6% | 33.3% |
| Operating Margin | -0.7% | 7.3% |
| Net Margin | -0.8% | 1.1% |
| Revenue YoY | 9.4% | 4.9% |
| Net Profit YoY | -892.9% | 866.7% |
| EPS (diluted) | $-0.11 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $209.6M | ||
| Q4 25 | $359.9M | $228.9M | ||
| Q3 25 | $374.5M | $203.0M | ||
| Q2 25 | $410.0M | $212.9M | ||
| Q1 25 | $377.8M | $199.8M | ||
| Q4 24 | $329.1M | — | ||
| Q3 24 | $398.2M | $205.7M | ||
| Q2 24 | $453.5M | $209.1M |
| Q1 26 | — | $2.3M | ||
| Q4 25 | $-2.8M | $12.2M | ||
| Q3 25 | $-2.6M | $-89.1M | ||
| Q2 25 | $31.4M | $6.9M | ||
| Q1 25 | $23.3M | $-300.0K | ||
| Q4 24 | $352.0K | — | ||
| Q3 24 | $22.3M | $-51.1M | ||
| Q2 24 | $38.9M | $1.4M |
| Q1 26 | — | 33.3% | ||
| Q4 25 | 7.6% | 34.0% | ||
| Q3 25 | 6.8% | 33.3% | ||
| Q2 25 | 14.3% | 36.0% | ||
| Q1 25 | 14.2% | 34.3% | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | 32.6% | ||
| Q2 24 | 17.9% | 32.0% |
| Q1 26 | — | 7.3% | ||
| Q4 25 | -0.7% | 8.6% | ||
| Q3 25 | -0.9% | -39.8% | ||
| Q2 25 | 7.7% | 10.4% | ||
| Q1 25 | 7.7% | 5.6% | ||
| Q4 24 | -3.9% | — | ||
| Q3 24 | 7.5% | 5.3% | ||
| Q2 24 | 11.5% | 4.4% |
| Q1 26 | — | 1.1% | ||
| Q4 25 | -0.8% | 5.3% | ||
| Q3 25 | -0.7% | -43.9% | ||
| Q2 25 | 7.7% | 3.2% | ||
| Q1 25 | 6.2% | -0.2% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 5.6% | -24.8% | ||
| Q2 24 | 8.6% | 0.7% |
| Q1 26 | — | $0.05 | ||
| Q4 25 | $-0.11 | $0.29 | ||
| Q3 25 | $-0.10 | $-2.15 | ||
| Q2 25 | $1.15 | $0.17 | ||
| Q1 25 | $0.86 | $-0.01 | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $0.82 | $-1.25 | ||
| Q2 24 | $1.43 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $19.8M | $125.6M |
| Total DebtLower is stronger | — | $367.6M |
| Stockholders' EquityBook value | $815.2M | $476.9M |
| Total Assets | $1.7B | $1.1B |
| Debt / EquityLower = less leverage | — | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $125.6M | ||
| Q4 25 | $19.8M | $155.1M | ||
| Q3 25 | $23.7M | $152.6M | ||
| Q2 25 | $18.4M | $223.0M | ||
| Q1 25 | $8.3M | $212.6M | ||
| Q4 24 | $19.6M | — | ||
| Q3 24 | $17.3M | $200.5M | ||
| Q2 24 | $12.1M | $190.0M |
| Q1 26 | — | $367.6M | ||
| Q4 25 | — | $367.5M | ||
| Q3 25 | — | $367.5M | ||
| Q2 25 | — | $567.2M | ||
| Q1 25 | — | $567.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $443.4M | ||
| Q2 24 | — | $443.1M |
| Q1 26 | — | $476.9M | ||
| Q4 25 | $815.2M | $472.6M | ||
| Q3 25 | $818.2M | $455.3M | ||
| Q2 25 | $823.7M | $549.7M | ||
| Q1 25 | $794.4M | $540.2M | ||
| Q4 24 | $774.6M | — | ||
| Q3 24 | $766.4M | $529.1M | ||
| Q2 24 | $746.6M | $581.2M |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $1.7B | $1.1B | ||
| Q3 25 | $1.7B | $1.1B | ||
| Q2 25 | $1.6B | $1.4B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.5B | $1.3B |
| Q1 26 | — | 0.77× | ||
| Q4 25 | — | 0.78× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $63.7M | $-16.1M |
| Free Cash FlowOCF − Capex | $36.1M | $-26.8M |
| FCF MarginFCF / Revenue | 10.0% | -12.8% |
| Capex IntensityCapex / Revenue | 7.7% | 5.1% |
| Cash ConversionOCF / Net Profit | — | -7.00× |
| TTM Free Cash FlowTrailing 4 quarters | $6.4M | $-13.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-16.1M | ||
| Q4 25 | $63.7M | $7.9M | ||
| Q3 25 | $26.6M | $7.7M | ||
| Q2 25 | $21.1M | $16.6M | ||
| Q1 25 | $11.4M | $9.5M | ||
| Q4 24 | $64.2M | — | ||
| Q3 24 | $57.3M | $25.9M | ||
| Q2 24 | $50.2M | $8.0M |
| Q1 26 | — | $-26.8M | ||
| Q4 25 | $36.1M | $2.3M | ||
| Q3 25 | $66.0K | $1.4M | ||
| Q2 25 | $-7.2M | $9.8M | ||
| Q1 25 | $-22.6M | $5.3M | ||
| Q4 24 | $29.8M | — | ||
| Q3 24 | $26.8M | $19.9M | ||
| Q2 24 | $16.7M | $3.3M |
| Q1 26 | — | -12.8% | ||
| Q4 25 | 10.0% | 1.0% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | -1.7% | 4.6% | ||
| Q1 25 | -6.0% | 2.7% | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 6.7% | 9.7% | ||
| Q2 24 | 3.7% | 1.6% |
| Q1 26 | — | 5.1% | ||
| Q4 25 | 7.7% | 2.4% | ||
| Q3 25 | 7.1% | 3.1% | ||
| Q2 25 | 6.9% | 3.2% | ||
| Q1 25 | 9.0% | 2.1% | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 7.7% | 2.9% | ||
| Q2 24 | 7.4% | 2.2% |
| Q1 26 | — | -7.00× | ||
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | 2.41× | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | 5.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
VREX
| Medical Segment | $144.8M | 69% |
| Industrial Segment | $64.8M | 31% |
